Antisense

Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Antisense.php on line 2
Antisense

LE WE PMID CA

Antisense

181

Antisense

Antibiotics (BASKET)

Antisense

Duchenne s muscular dystrophy

Locked nucleic acid

RNA (MicroRNA)

RNA (non coding)

RNA (Splicing)

Splicing

2004 1	2'-O,4'-C-ethylene-bridged nucleic acids (ENA) as next-generation antisense and antigene agents. [15056846] Biol Pharm Bull 27(4): 453-6 (2004)
1998 2	Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes. [9841677] Microbiol Mol Biol Rev 62(4): 1415-34 (1998)
1998 3	Gene therapy for infectious diseases. [9457428] Clin Microbiol Rev 11(1): 42-56 (1998)
2009 4	Improved applications of the tetracycline-regulated gene depletion system. [20103842] Biosci Trends 3(5): 161-7 (2009)
2007 5	Regulating gene expression with light-activated oligonucleotides. [17245489] Mol Biosyst 3(2): 100-10 (2007)
2008 6	Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics. [19787090] Gene Regul Syst Bio 2(): 275-95 (2008)
2008 7	DNAzyme technology and cancer therapy: cleave and let die. [18281510] Mol Cancer Ther 7(2): 243-51 (2008)
2002 8	Antisense oligonucleotides: basic concepts and mechanisms. [12489851] Mol Cancer Ther 1(5): 347-55 (2002)
1988 9	Oligodeoxynucleotides as inhibitors of gene expression: a review. [3282648] Cancer Res 48(10): 2659-68 (1988)
2009 10	A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground. [19139297] Arch Neurol 66(1): 32-8 (2009)
2001 11	Triplex forming oligonucleotides: sequence-specific tools for gene targeting. [11673407] Hum Mol Genet 10(20): 2243-51 (2001)
2000 12	Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function. [11086018] J Clin Invest 106(10): 1189-95 (2000)
2000 13	Therapeutic applications of transcription factor decoy oligonucleotides. [11067859] J Clin Invest 106(9): 1071-5 (2000)
1997 14	Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants. [9252130] Hepatology 26(2): 251-5 (1997)
1996 15	A hitchhiker's guide to antisense and nonantisense biochemical pathways. [8938189] Hepatology 24(6): 1517-29 (1996)
1999 16	Antisense and nuclear medicine. [10210231] J Nucl Med 40(4): 693-703 (1999)
2001 17	Prospects of chimeric RNA-DNA oligonucleotides in gene therapy. [11702006] J Biomed Sci 8(6): 439-45 (2001)
2003 18	Design and applications of modified oligonucleotides. [12563516] Braz J Med Biol Res 36(2): 143-51 (2003)
2004 19	Progress in the development of nucleic acid therapeutics for cancer. [14726654] Cancer Biol Ther 3(1): 4-12 (2004)
2011 20	Oligonucleotides decoy to NF-kappaB: becoming a reality? [21878187] Discov Med 12(63): 97-105 (2011)
2003 21	Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. [12925686] J Clin Invest 112(4): 481-6 (2003)
2003 22	Antisense technologies. Improvement through novel chemical modifications. [12694176] Eur J Biochem 270(8): 1628-44 (2003)
2009 23	Locked nucleic acid as a novel class of therapeutic agents. [19458498] RNA Biol 6(3): 321-3 (2009)
2009 24	Regulatory roles of natural antisense transcripts. [19638999] Nat Rev Mol Cell Biol 10(9): 637-43 (2009)
2010 25	Progress in therapeutic antisense applications for neuromuscular disorders. [19809477] Eur J Hum Genet 18(2): 146-53 (2010)
2010 26	Crystallographic studies of chemically modified nucleic acids: a backward glance. [20087997] Chem Biodivers 7(1): 60-89 (2010)
2011 27	Deoxyribozymes: new therapeutics to treat central nervous system disorders. [21977013] Front Mol Neurosci 4(-): 25 (2011)
2009 28	Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. [18813282] Mol Ther 17(3): 548-53 (2009)
2010 29	MicroRNA sponges: progress and possibilities. [20855538] RNA 16(11): 2043-50 (2010)
2007 30	Modulating the expression of disease genes with RNA-based therapy. [17604456] PLoS Genet 3(6): e109 (2007)
2002 31	Assessment of the genotoxic potential of ISIS 2302: a phosphorothioate oligodeoxynucleotide. [11971990] Mutagenesis 17(3): 201-9 (2002)
2009 32	Progress toward therapy with antisense-mediated splicing modulation. [19330717] Curr Opin Mol Ther 11(2): 116-23 (2009)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Antisense.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Antisense.php on line 92